SM
EPRS

Southport Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Southport Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$135K – 47
2016
Q1 		$135K Buy
50,000
+25,000
+100% +$70.2K 0.22% 34
2015
Q4 		$77K Hold
25,000
– – 0.14% 33
2015
Q3 		$111K Sell
25,000
-25,000
-50% -$147K 0.22% 35
2015
Q2 		$286K Buy
50,000
+25,000
+100% +$171K 0.37% 44
2015
Q1 		$224K Buy
+25,000
New +$201K 0.23% 43

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Southport Management's EPRS Position: Q2 2016 in Review

Southport Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 50,000 shares — an estimated $135K sold.

Southport Management first reported a position in EPRS in Q1 2015 and held it in 5 quarters. The position peaked at $286K in Q2 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • Southport Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Southport Management sold 50,000 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $135K.
  • Southport Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 5 quarters.
  • Southport Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $286K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Southport Management's 13F filing for Q2 2016, filed 12 Aug 2016.